NCT06475755 2024-06-26
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
Phase 2 Not yet recruiting
Tang-Du Hospital
Hunan Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Xinqiao Hospital of Chongqing